NCT06857669 Clinical Explorative Optical Breast Investigations
| NCT ID | NCT06857669 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | Benign Breast Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2020-12-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2020-12-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates diffuse reflectance spectroscopy and photoacoustic imaging for differentiating healthy, benign, and malignant breast tissue by identifying their optical profiles.
Eligibility Criteria
Inclusion Criteria: * solitary malignant or benign biopsy verified tumour \> 1 cm * understands written and oral Swedish Exclusion Criteria: * previous breast surgery * has received neoadjuvant chemotherapy * skin burns in on the chest
Contact & Investigator
Sophia Zackrisson, MD, PhD
PRINCIPAL INVESTIGATOR
Region Skane, Lund University
Frequently Asked Questions
Who can join the NCT06857669 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Benign Breast Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06857669 currently recruiting?
Yes, NCT06857669 is actively recruiting participants. Contact the research team at sophia.zackrisson@med.lu.se for enrollment information.
Where is the NCT06857669 trial being conducted?
This trial is being conducted at Malmö, Sweden.
Who is sponsoring the NCT06857669 clinical trial?
NCT06857669 is sponsored by Region Skane. The principal investigator is Sophia Zackrisson, MD, PhD at Region Skane, Lund University. The trial plans to enroll 90 participants.